EU's CHMP recommends Amgen's Prolia for two indications
This article was originally published in Scrip
Executive Summary
The EU's CHMP has endorsed Amgen's Prolia (denosumab) for the treatment of osteoporosis in postmenopausal women at risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.